EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM

Peter Valent, Karin Hartmann, Gregor Hoermann, Andreas Reiter, Iván Alvarez-Twose, Knut Brockow, Patrizia Bonadonna, Olivier Hermine, Marek Niedoszytko, Melody C Carter, Joseph H Butterfield, Frank Siebenhaar und 17 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2024-12 · 12 (12) · 3250-3260.e5

DOI: 10.1016/j.jaip.2024.08.044 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-12. Verfasst von Peter Valent und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institu…. Hauptthemen laut MEDLINE: Mastocytosis, World Health Organization. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, National Institute of Allergy and Infectious Diseases, Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mastocytosis is a clonal myeloid disorder defined by an increase and accumulation of mast cells (MCs) in one or multiple organ systems. The complex pathology of mastocytosis results in variable clinical presentations, courses, and outcomes. The World Health Organization (WHO) divides the disease into cutaneous mastocytosis (CM), several forms of systemic mastocytosis (SM), and MC sarcoma. In most patients with SM, a somatic KIT mutation, usually D816V, is identified. Patients diagnosed with CM or nonadvanced SM, including indolent SM, have a near-normal life expectancy, whereas those with advanced SM, including aggressive SM and MC leukemia, have limited life expectancy. Since 2001, a multidisciplinary consensus group consisting of experts from the European Competence Network on Mastocytosis and the American Initiative in Mast Cell Diseases has supported the field by developing diagnostic criteria for mastocytosis. These criteria served as the basis for the WHO classification of mastocytosis over 2 decades. More recently, an International Consensus Classification group proposed slightly modified diagnostic criteria and a slightly revised classification. In this article, these changes are discussed. Furthermore, we propose harmonization among the proposals of the American Initiative in Mast Cell Diseases/European Competence Network on Mastocytosis consensus group, WHO, and the International Consensus Classification Group. Such harmonization will facilitate comparisons of retrospective study results and the conduct of prospective trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MastocytosisWorld Health OrganizationHumansMast CellsProto-Oncogene Proteins c-kitMastocytosis, Systemic

Stichwörter der Autor:innen

AIMDiagnostic algorithmsDiagnostic criteriaECNMHarmonizationICCKITMastocytosisPersonalized medicineTryptaseWHO

Substanzen

Proto-Oncogene Proteins c-kit

Autor:innen und Institutionen

  • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna,…
  • Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; MLL Munich Leukemia Laboratory, Munich, Germany.
  • Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
  • Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain.
  • Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany.

Förderung

  • Austrian Science Fund
  • National Institute of Allergy and Infectious Diseases
  • Division of Intramural Research
  • National Institutes of Health

Zitieren

APA

Valent, P., Hartmann, K., Hoermann, G., Reiter, A., Alvarez-Twose, I., Brockow, K., Bonadonna, P., Hermine, O., Niedoszytko, M., Carter, M. C., Butterfield, J. H., Siebenhaar, F., Zanotti, R., Radia, D. H., Castells, M., Sperr, W. R., Broesby-Olsen, S., Triggiani, M., Schwartz, L. B., …, & Akin, C. (2024). Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM. The Journal of Allergy and Clinical Immunology: In Practice, 12(12), 3250-3260.e5. https://doi.org/10.1016/j.jaip.2024.08.044

Vancouver

Valent P, Hartmann K, Hoermann G, Reiter A, Alvarez-Twose I, Brockow K, et al. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(12):3250-3260.e5. doi:10.1016/j.jaip.2024.08.044

BibTeX
@article{Valent2024,
  author = {Valent, Peter and Hartmann, Karin and Hoermann, Gregor and Reiter, Andreas and Alvarez-Twose, Iván and Brockow, Knut and Bonadonna, Patrizia and Hermine, Olivier and Niedoszytko, Marek and Carter, Melody C and Butterfield, Joseph H and Siebenhaar, Frank and Zanotti, Roberta and Radia, Deepti H and Castells, Mariana and Sperr, Wolfgang R and Broesby-Olsen, Sigurd and Triggiani, Massimo and Schwartz, Lawrence B and George, Tracy I and Gülen, Theo and Sotlar, Karl and Gotlib, Jason and Galli, Stephen J and Horny, Hans-Peter and Metcalfe, Dean D and Orfao, Alberto and Arock, Michel and Akin, Cem},
  title = {Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  volume = {12},
  number = {12},
  pages = {3250--3260.e5},
  doi = {10.1016/j.jaip.2024.08.044}
}
Kostenlos starten →